Balyasny Asset Management
TNDM icon

Balyasny Asset Management’s Tandem Diabetes Care TNDM Stock Holding History

Balyasny Asset Management’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65,000
Closed -$2.92M – 3156
2022
Q4 		$2.92M Buy
+65,000
New +$2.94M 0.01% 1255

Other funds holding TNDM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's TNDM Position: Q1 2026 in Review

Balyasny Asset Management sold out of Tandem Diabetes Care (TNDM) in Q1 2026, closing a stake of 262,788 shares — an estimated $5.78M sold.

Balyasny Asset Management first reported a position in TNDM in Q1 2018 and held it in 22 quarters. The position peaked at $32.4M in Q3 2020. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

  • Balyasny Asset Management reported no remaining Tandem Diabetes Care position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 262,788 Tandem Diabetes Care shares in Q1 2026, an estimated $5.78M.
  • Balyasny Asset Management first reported a position in Tandem Diabetes Care in Q1 2018 and held it in 22 quarters.
  • Balyasny Asset Management's Tandem Diabetes Care position peaked at $32.4M in Q3 2020.
  • 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.